Jacobs Levy Equity Management
OSIR

Jacobs Levy Equity Management’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Jacobs Levy Equity Management’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,032
Closed -$117K – 1254
2016
Q2 		$117K Sell
23,032
-34,868
-60% -$188K ﹤0.01% 1082
2016
Q1 		$331K Buy
+57,900
New +$404K 0.01% 841

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's OSIR Position: Q3 2016 in Review

Jacobs Levy Equity Management sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q3 2016, closing a stake of 23,032 shares — an estimated $117K sold.

Jacobs Levy Equity Management first reported a position in OSIR in Q1 2016 and held it in 2 quarters. The position peaked at $331K in Q1 2016. 63 funds tracked by Wall St. Rank hold OSIR as of Q3 2016.

  • Jacobs Levy Equity Management reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 23,032 Osiris Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $117K.
  • Jacobs Levy Equity Management first reported a position in Osiris Therapeutics, Inc. Common Stock in Q1 2016 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Osiris Therapeutics, Inc. Common Stock position peaked at $331K in Q1 2016.
  • 63 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2016, filed 14 Nov 2016.